Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-849
Abstract: Introduction TGD001 is a novel thrombolytic fusion protein that binds with high affinity to von Willebrand factor (VWF) for targeted plasminogen activation. TGD001 is comprised of an antibody fragment that binds to VWF, fused with… read more here.
Keywords: willebrand factor; trial; well tolerated; tgd001 ... See more keywords